The efficacy of Ensacove was evaluated in the eXALT3 study (NCT02767804), a randomized, controlled trial involving 290 ALK-positive NSCLC patients who had not received prior ALK-targeted therapy [193]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.